Biorepository: Type 1 Diabetes

People with T1D making a difference

What is BRI’s Diabetes Biorepository?

The Diabetes Biorepository is a confidential list of people with type type 1 diabetes (T1D) who donate samples and provide health information for scientific research. This library of samples and information helps our scientists study how and why T1D starts and make progress toward prevention and better treatments. 

Participate in Diabetes Research

We invite individuals with T1D to participate in this research to help us improve our understanding of diabetes and immune-mediated diseases.

We are also looking for family members of all ages who do not have type Type 1 diabetes or another immune-mediated or autoimmune disease, to join our Healthy Volunteer Registry.

Participating in research typically involves a 45-60 -minute visit to BRI in downtown Seattle. Our team will collect a blood sample and ask questions about your personal and family medical history. All samples and information are kept confidential. Learn more: Biorepository FAQ

Learn more about type 1 diabetes.

Are you living with or at risk of developing T1D?

Consider donating to our biorepository or participating in our T1D research. 
Sandra Lord
Clinical Director, Center for Interventional Immunology

Sandra Lord, MD

Clinical Director, Center for Interventional Immunology; Director, Clinical Research Center
View Full Bio
By the Numbers


Unique T1D Volunteers


Samples, some longitudinal

Labs Studying Type 1 Diabetes

Buckner Lab Main

Buckner Lab

The Buckner Lab is focused on identifying the underlying mechanisms by which regulation of the adaptive immune response fails or is overcome in the setting of human autoimmunity. 
View Lab
Campbell Lab Main

Campbell Lab

The Campbell laboratory is interested in understanding the basis for T cell activation, function and tolerance.
View Lab
Cerosaletti Research Project Main - Autoreactive T cells in type 1 diabetes

Cerosaletti Lab

Dr. Cerosaletti’s research is focused on the role of the adaptive immune system in the development and progression of immune mediated diseases and the response to treatment.
View Lab
Greenbaum Lab Main Image

Greenbaum Lab

Our group focuses on prediction and prevention of type 1 diabetes (T1D) as well as discovery and validation of biomarkers of disease progression and response to therapy.
View Lab
James Lab Main

James Lab

The James lab is working to develop an increasingly in depth knowledge of autoreactive T cell responses by examining the characteristics of the epitope specific cells involved in autoimmune diseases through robust multi-parameter assays and also at the single cell level.
View Lab
Kwok Research Project Main - DNA-barcoded HLA class II tetramers

Kwok Lab

The Kwok lab uses tetramers and other antigen specific T cell assays to examine autoreactive T cells in  autoimmune diseases in order to provide insights into disease mechanisms and identify strategies for disease intervention.
View Lab
Linsley Lab Main

Linsley Lab

Our goal is to develop and use cutting edge systems biology approaches to elucidate molecular signatures of complex immune diseases, understand the mechanisms of disease, and identify the right therapy for the right patient.
View Lab
Long Lab Main

Long Lab

The Long Lab focuses on understanding mechanisms of tolerance, why they are lost in autoimmunity, and how tolerance can be augmented with therapy.
View Lab
Speake Research Project Main - TrialNet Pathway to Prevention

Speake Lab

The Speake group is interested in advancing clinical research – especially in type 1 diabetes, but also in the context of other immune-mediated diseases.
View Lab
Blog Main Image - BRI Samples Frozen Hand Tongs

Collaborate with us

We want to advance the science to predict, prevent, reverse and ultimately cure T1D and seek out opportunities to collaborate.  We have the technology, participants, expertise, samples and desire.  Learn about all of the ways we collaborate, we look forward to hearing from you.
Learn more about opportunities for collaboration


News Science in Seattle

Science in Seattle: A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab

Read the publication ➡
News Main Image - Puget Sound Business Journal

Benaroya Research Institute’s Dr. Carla Greenbaum Receives Puget Sound Business Journal Lifetime Achievement Award

Read More
News Scripps Research

Monitoring T cells may allow prevention of type 1 diabetes

Read More ➡

Blog Stories

Blog Main Image - T1D Diabetes Monitoring Blood Sugar Test
November 17, 2022

Teplizumab FAQ: Your Questions Answered About New Therapy to Delay T1D

Scientists at the Benaroya Research Institute (BRI) and TrialNet, a global type 1 diabetes (T1D) research consortium, have spent decades working to answer a bold question: Can we stop T1D before it starts?

Read Article
Blog Main Image - BRI Researcher Woman Participant Man Blood Draw
June 15, 2021

New Drug Aims to Retrain the Immune System in T1D

What if doctors could treat type 1 diabetes (T1D) by teaching the immune system to stop attacking cells in the pancreas? BRI researchers are working with the pharmaceutical company Novo Nordisk and global research consortium T1D TrialNet, testing a new approach that aims to do just that.

Read Article
Blog Main Image - Clinician Holding Prescription Drugs
June 22, 2020

Is Hydroxychloroquine Safe for Autoimmune Diseases?

COVID-19 has put a therapy called hydroxychloroquine in the spotlight — and, at the same time, shrouded it in confusion.

Read Article

Immuno-what? Hear the latest from BRI

Keep up to date on our latest research, new clinical trials and exciting publications.